HCl Sta ethyl ester | 84851-46-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: HCl Sta ethyl ester
• 英文别名: (S,S)-Sta-OEt hydrochloride；NH2-(S,S)-Sta-OEt*HCl；Statine ethyl ester hydrochloride；ethyl (3S,4S)-4-amino-3-hydroxy-6-methylheptanoate;hydrochloride
• CAS: 84851-46-7
• 化学式: C₁₀H₂₁NO₃*ClH
• 分子量: 239.743
• InChiKey: PDEDGAXYRXFGRL-OZZZDHQUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  72.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  HCl Sta ethyl ester 在 盐酸 、 sodium hydroxide 、 1-羟基苯并三唑 、 N,N-二异丙基乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 38.0h， 生成 (S)-2-((S)-2-{(3S,4S)-4-[(S)-2-Amino-3-(1-benzyloxymethyl-1H-imidazol-4-yl)-propionylamino]-3-hydroxy-6-methyl-heptanoylamino}-propionylamino)-3-phenyl-propionic acid methyl ester; hydrochloride
  参考文献：
  名称：

  Inhibition of porcine pepsin by two substrate analogs containing statine. The effect of histidine at the P2 subsite on the inhibition of aspartic proteinases

  摘要：

  Two new inhibitors, 4 and 5, of the aspartic proteinase porcine pepsin were synthesized. These compounds, which span the P4-P'3 binding subsites of the enzyme, were derived by replacing the Nph-Phe dipeptidyl unit of a good pepsin substrate, H2N-Phe-Gly-His-Nph-Phe-Ala-Phe-OMe (3), with statine [(3S,4S)-4-amino-3-hydroxy-6-methylheptanoic acid, Sta]. Hexapeptide 5, H2N-Phe-Gly-Val-(S,S)-Sta-Ala-Phe-OMe, is an extremely potent inhibitor of pepsin with a Ki value less than 1 nM. This result is consistent with the proposal that statine functions as a bioisosteric replacement for a substrate dipeptidyl unit. Compound 4, which contains His at P2, is 2 orders of magnitude less active than the valine analogue 5 (Ki = 150 nM). The factor for the decrease in binding to pepsin effected by replacement of Val by His at P2 parallels the ratio of protonated vs unprotonated imidazole group in peptide 4 at pH 4, according to the Henderson-Hasselbach equation. This result suggests that a positively charged side chain at P2 is undesirable for maximum pepsin inhibition. Kinetic constants for several known inhibitors of pepsin and renin are presented that demonstrate that the effect of His incorporation at P2 on pepsin inhibition depends upon the peptide sequence and that the effect is considerably different for renin inhibitors. We further suggest that the high selectivity of potent renin inhibitors known to be only weak pepsin and cathepsin D inhibitors is due in part to the extent of histidine protonation at P2 arising from pH differences in the inhibition kinetics assay of renin (neutral conditions) compared to other aspartic proteinases (acid pH 2-4).

  DOI：

  10.1021/jm00398a022
• 作为产物：
  描述：

  2-甲基-2-丙基[(2S)-4-甲基-1-氧代-2-戊烷基]氨基甲酸酯 在 盐酸 、 lithium hexamethyldisilazane 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.17h， 生成 HCl Sta ethyl ester
  参考文献：
  名称：

  Potent and selective inhibitors of an aspartyl protease-like endothelin converting enzyme identified in rat lung

  摘要：

  Two structurally distinct series of potent and selective inhibitors of an aspartyl protease-like endothelin converting enzyme (ECE) activity identified in the rat lung have been developed. Pepstatin A, which potently inhibits the rat lung ECE, served as the basis for the first series. Alternatively, selected renin inhibitors containing the dihydroxyethylene moiety were shown to be inhibitors of rat lung activity. Subsequent modifications improved inhibition of the rat lung ECE while eliminating renin activity. Both series of ECE inhibitors demonstrated a range of selectivity over Cathepsin D. Water-solubilizing moieties were appended onto selected compounds to facilitate in vivo testing. Partial reduction of the pressor response to exogenously administered Big ET-1 was observed with selected rat lung ECE inhibitors.

  DOI：

  10.1021/jm00056a007

文献信息

• Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analog inhibitors containing a novel analog of statine
  作者：Joshua Boger、Linda S. Payne、Debra S. Perlow、Nancy S. Lohr、Martin Poe、Edward H. Blaine、Edgar H. Ulm、Terry W. Schorn、Bruce I. LaMont

  DOI：10.1021/jm00150a007

  日期：1985.12

  Analogues of the renin octapeptide substrate were synthesized in which replacement of the scissile dipeptide with (3S,4S)-4-amino-3-hydroxy-6-methylheptanoic acid (statine, Sta) transformed the substrate sequence into potent, transition-state analogue, competitive inhibitors of renin. Synthesis and incorporation of the cyclohexylalanyl analogue of Sta, (3S,4S)-4-amino-5-cyclohexyl-3-hydroxypentanoic

  合成了肾素八肽底物的类似物，其中用（3S，4S）-4-氨基-3-羟基-6-甲基庚酸（statine，Sta）取代易裂二肽将底物序列转变为有效的过渡态类似物，肾素的竞争性抑制剂。Sta的环己基丙氨酰基类似物（3S，4S）-4-氨基-5-环己基-3-羟基戊酸（ACHPA）的合成和掺入提供了迄今为止报道的最有效的肾素抑制剂，包括N-异戊基-L-组氨酸-L-脯氨酰基-L-苯丙氨酰基-L-组氨酸-ACHPA-L-亮氨酰-L-苯丙氨酰胺[Iva-His-Pro-Phe-His-ACHPA-Leu-Phe-NH2,3]，肾素抑制Ki = 1.6 X 10（-10）M（人肾素），IC50 = 1.7 X 10（-10）M（人血浆肾素），IC50 = 1.9 X 10（-9）M（犬血浆肾素）和IC50 = 2.1 X 10（-8）M（大鼠血浆肾素）。含有ACHPA的这种抑制剂3，与人肾素的效价比含Sta的抑
• Synthesis of analogs of pepstatin. Effect of structure in subsites P1', P2', and P2 on inhibition of porcine pepsin
  作者：Daniel H. Rich、Francesco G. Salituro

  DOI：10.1021/jm00360a022

  日期：1983.6

  A series of pepstatin analogues having structural variations in the P2', P1', and P2 positions have been synthesized and tested for inhibition of porcine pepsin. The standard peptide for this study was Iva-Sta-Val-Ala-Iaa. Structural variations in the P2' and P1' positions have relatively little effect on Ki; however, small variations in the P2 position have a more dramatic effect on Ki and time-dependent

  已经合成了一系列在P2′，P1′和P2位置具有结构变化的胃抑素类似物，并测试了其对猪胃蛋白酶的抑制作用。这项研究的标准肽是Iva-Sta-Val-Ala-Iaa。P2'和P1'位置的结构变化对Ki的影响相对较小；然而，P2位置的微小变化对Ki和时间依赖性抑制具有更显着的影响。还合成了一系列胃抑素片段，并测试了其对猪胃蛋白酶的抑制作用。
• Synthesis of the novel .pi.-(benzyloxymethyl)-protected histidine analog of statine. Inhibition of penicillopepsin by pepstatin-derived peptides containing different statine side-chain derivatives
  作者：Juergen Maibaum、Daniel H. Rich

  DOI：10.1021/jm00127a028

  日期：1989.7

  inhibitor 3 and 2-3 times more potent than the new (3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid (AHPPA) analogue 17 (Ki = 1.5 x 10(-8) M). However, compound 16, which has an imidazole residue at the P1 position, is a significantly weaker inhibitor of the enzyme than the corresponding analogues with the lysine (5) and ornithine (6) side chains at P1. Considerations that led to the synthesis of 16 and

  衍生自一种新的他汀（Sta），（3S，4S）-4-氨基-3-羟基-5-（咪唑-4-基）戊酸（HiSta，20）的组氨酸侧链类似物的天冬氨酸蛋白酶抑制剂的合成），被报告。Boc-HiSta（BOM）-OMe（7）以Boc-His（pi-BOM）-OH的总收率为16％的方式制备，方法是形成四酸衍生物11并用NaBH4进行立体选择性顺式还原成4-羟基内酰胺12 ·通过DCC / HOBt预活化方法，从酯7（对映体纯度ee ＝ 88-90％）上除去Boc基团，并偶联至三肽链段Iva-Val-Val-OH（13），然后氢解除去pi-。碳上Pd（OH）2上的BOM组得到Iva-Val-Val-HiSta-OMe（16）。这种新的肽16是真菌天冬氨酸蛋白酶Penicillopsepsin的非常有效的抑制剂（Ki = 4。5 x 10（-9）M），其活性是同类含Sta的抑制剂3的10倍，且效力是新的（3S
• Renin inhibitors containing statine or derivatives thereof
  申请人：Pfizer Inc.

  公开号：US04749687A1

  公开（公告）日：1988-06-07

  A series of novel peptide and polypeptide derivatives containing statine or derivatives thereof (e.g., aminostatine, cyclostatine) are disclosed that are useful for inhibiting the angiotensinogen-cleaving action of the enzyme renin. Of particular interest are compounds possessing the N-terminal sequence -Pro-Phe-His-Sta-Lys with the terminal proline nitrogen bonded to an amino-protecting acyl moiety or compounds possessing the N-terminal sequence -R-Phe-His-Sta-Lys- wherein R represents an amino protecting acyl group.

  本发明揭示了一系列包含statine或其衍生物（例如，aminostatine，cyclostatine）的新型肽和多肽衍生物，其对于抑制酶renin的血管紧张素原裂解作用非常有用。特别感兴趣的是具有N-末端序列-Pro-Phe-His-Sta-Lys且末端脯氨酸氮原子与氨基保护酰基团结合的化合物，或具有N-末端序列-R-Phe-His-Sta-Lys-的化合物，其中R代表氨基保护酰基团。
• Polypeptide derivatives containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
  申请人：PFIZER INC.

  公开号：EP0212903A2

  公开（公告）日：1987-03-04

  Polypeptide derivatives containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues are of the formula: wherein, for example in a preferred embodiment R is t-butyloxycarbonyl, m and n are each 0 or 1, their sum being at least 1; R is cyclohexylmethyl; R2 is 2-methylpropyl, 2-methyl-2--propenyl, benzyl, 4-chlorobenzyl, 3-chlorobenzyl, 4-methylbenzyl, 4-methoxybenzyl, 3,4-dichlorobenzyl, 2-chlorobenzyl or cyclohexylmethyl; R3 is hydrogen; R4 is hydrogen, methyl, 4-aminobutyl, 2-carboxyethyl, 3-(ethoxycarbonyl)propyl or 3-(benzyloxycarbonyl)propyl; W is phenylalanyl, W1 is histidyl and W2 is lysyl. These compounds are useful for inhibiting the angiotensinogen cleaving action of the enzyme renin having particular utility in the treatment of hypertension.

  含有 5-氨基-2,5-二取代-4-羟基戊酸残基的多肽衍生物为以下式子： 其中，例如在一个优选的实施方案中，R是叔丁氧羰基，m和n各为0或1，它们的总和至少为1；R是环己基甲基；R2是2-甲基丙基、2-甲基-2-丙烯基、苄基、4-氯苄基、3-氯苄基、4-甲基苄基、4-甲氧基苄基、3,4-二氯苄基、2-氯苄基或环己基甲基；R3 是氢；R4 是氢、甲基、4-氨基丁基、2-羧乙基、3-（乙氧基羰基）丙基或 3-（苄氧基羰基）丙基；W 是苯丙氨酰，W1 是组氨酰，W2 是赖氨酰。 这些化合物可用于抑制肾素酶的血管紧张素原裂解作用，特别适用于治疗高血压。